{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.9402","value":"14.370"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"title":"Baseline oGTT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6354","value":"-2.117"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Change from Baseline in oGTT at Week 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"Plasma glucose was measured using the 2-hour oGTT.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the mITT-OL Population who had DM/IGT with or without HTN at Baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in 2-hour Plasma Glucose During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"mmol/L"}